TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34197589
Drug: Dopamine D2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/3 receptor antagonist amisulpride (400 mg)
Study: 34197589
Drug: Dopamine D2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D2/3 receptor agonist pramipexole (0.5 mg)
Study: 32075830
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 20 mg per day for 5 days
Study: 33612554
Drug: 2nd-generation drug-eluting
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2nd-generation drug-eluting stents (n=59)
Study: 34106454
Drug: platinum chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum chemotherapy and durvalumab
Study: 34106454
Drug: chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemo-immunotherapy
Study: 32346001
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (60% of patients)
Study: 34822104
Drug: Venetoclax (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400-800 mg) administered with R-CHOP for eight 21-day cycles (cycle 1: days 4-10; cycles 2-8: days 1-10)
Study: 34822104
Drug: Venetoclax (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400-800 mg)
Study: 34822104
Drug: Venetoclax (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (800 mg) with R-CHOP
Study: 35363510
Drug: Selumetinib (MEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (MEK inhibitor), administered twice daily for 28-day cycles until disease progression or intolerable toxicity.
Study: 35363510
Drug: Selumetinib (MEK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (MEK inhibitor)
Study: 34247027
Drug: Melissa essential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melissa essential oil (inhaled 2 drops for 10 min with 90-min intervals)
Study: 34247027
Drug: Placebo (sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sunflower oil inhaled 2 drops for 10 min with 90-min intervals)
Study: 33245118
Drug: Financial incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Financial incentives for dietary self-monitoring and weekly weight loss
Study: 32033582
Drug: Buprenorphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (10 μg/kg or 15 μg/kg)
Study: 32033582
Drug: Naloxone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (titrated doses)
Study: 33944597
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (2 mL, 1 mL/nostril)
Study: 33944597
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (2 mL, 1 mL/nostril)
Study: 33944597
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% NaCl) solution (2 mL)
Study: 35086692
Drug: KVD900 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 600 mg tablet under fasted conditions
Study: 35086692
Drug: KVD900 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 600 mg tablet
Study: 35086692
Drug: KVD900 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 600 mg dose
Study: 35086692
Drug: KVD900 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: KVD900 (various doses)
Study: 32107938
Drug: Lipid-lowering agents
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering agents (high-intensity statins)
Study: 34791805
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg PEG rhG‐CSF
Study: 34791805
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (5 μg/kg rhG‐CSF administered when ANC reached grade 3)
Study: 32098573
Drug: Fluoropyrimidine-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine-based neoadjuvant chemotherapy (NACT) administered to 45 patients for a median of 8 weeks prior to surgical resection.
Study: 33940235
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg−1 of low dose rocuronium
Study: 32384953
Drug: nAg‐NPs (≥0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nAg‐NPs (≥0.5 g/mL)
Study: 32384953
Drug: nAg‐NPs (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: nAg‐NPs (0.05 g/mL)
Study: 32384953
Drug: nAg‐NPs (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nAg‐NPs (5 g/mL)
Study: 32979978
Drug: Gabapentin (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (titrated to a maximum dose of 2700 mg daily)
Study: 35697547
Drug: Intraoperative lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative lidocaine infusion (continuous infusion of 2 mg kg‐1 h‐1 after 1.5 mg kg‐1 bolus at induction of anaesthesia)
Study: 32385495
Drug: Active reference
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active reference treatment (not specified)
Study: 32917288
Drug: Mistletoe extract
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extract (0.01 to 20 mg subcutaneously three times per week for 9 months)
Study: 33109233
Drug: Neo-adjuvant lapatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant lapatinib, trastuzumab, or their combination plus paclitaxel
Study: 39369249
Drug: Intravenous induction
Normalized name: Intravenous induction agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous induction
Study: 36047598
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg intravenous ferric carboxymaltose
Study: 36047598
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg intravenous ferric carboxymaltose
Study: 32334548
Drug: mDCF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mDCF plus atezolizumab (800 mg every 2 weeks)
Study: 33129363
Drug: Favipiravir and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir and Hydroxychloroquine combination
Study: 34610151
Drug: Adjunctive Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Er:YAG laser (ERL) in non-surgical periodontal therapy (NSPT)
Study: 34610151
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment in non-surgical periodontal therapy (NSPT)
Study: 33496530
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy at baseline
Study: 34836152
Drug: Common Bean
Normalized name: Bean
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common Bean Baked Snack (CBBS) consumption (32 g for four weeks)
Study: 36089442
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of force
Study: 36089442
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of force
Study: 36089442
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g or 150 g of force
Study: 35405603
Drug: Probiotic kefir
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic kefir (180 mL/d)
Study: 32621587
Drug: Hydrocortisone treatment
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone treatment regimens (three or four times daily)
Study: 34269632
Drug: Interventions designed
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interventions designed to enhance treatment engagement
Study: 35080497
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (8 weeks of placebo treatment unrelated to PA and FVC)
Study: 32159187
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch enriched cookies (16 g of RS per day)
Study: 34813821
Drug: Traditional training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional training (TRAD-G)
Study: 36297014
Drug: BCAAs (0.17
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs (0.17 g/kg BCAAs + 0.17 g/kg glucose)
Study: 36297014
Drug: Placebo (0.34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.34 g/kg glucose)
Study: 34447267
Drug: Celecoxib oral
Normalized name: celecoxib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib oral solution (120 mg, 4.8 mL)
Study: 35671039
Drug: Efpeglenatide 2
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 2 mg
Study: 35671039
Drug: Efpeglenatide 4
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 4 mg
Study: 35671039
Drug: Efpeglenatide 6
Normalized name: Efpeglenatide
DrugBank: Efpeglenatide (DB15650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efpeglenatide 6 mg
Study: 32891292
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy integrated with family recollection (15 minutes, twice a day for 6 days)
Study: 33265920
Drug: Acyclovir (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (750 mg/m2 intravenously)
Study: 33265920
Drug: Acyclovir (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (1600 mg per day orally)
Study: 33265920
Drug: Acyclovir (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (250 mg/m2 per day intravenously)
Study: 36115256
Drug: Somatostatin analogue
Normalized name: Somatostatin analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin analogue therapy (SSA)
Study: 35015806
Drug: High-protein yogurt
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein yogurt (10 g protein/100 g)
Study: 35015806
Drug: Normal-protein yogurt
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein yogurt (3.5 g protein/100 g)
Study: 33368338
Drug: High-dose valaciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valaciclovir (900 mg, three times daily for 10 days)
Study: 33368338
Drug: Low-dose valaciclovir
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose valaciclovir (300 mg, two times daily for 10 days)
Study: 33368338
Drug: High-dose valaciclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose valaciclovir
Study: 32419473
Drug: Lenvatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib treatment for patients weighing <60 kg
Study: 32419473
Drug: Lenvatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib treatment for patients weighing ≥60 kg
Study: 35212278
Drug: Zuo acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuo acupuncture treatment plus lifestyle interventions
Study: 33486596
Drug: Reduced 2016‐AAO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced 2016‐AAO dose (2–3 mg/kg/day)
Study: 33486596
Drug: Full 2016‐AAO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full 2016‐AAO dose (5 mg/kg/day)
Study: 33653121
Drug: Midazolam (0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.045 mg/kg over 40 minutes)
Study: 34060462
Drug: Three-day post-operative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day post-operative course of oral antibiotics
Study: 34060462
Drug: Three-day post-operative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-day post-operative course of intravenous antibiotics
Study: 35063943
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with frontline carboplatin and paclitaxel chemotherapy
Study: 32979860
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid cream
Study: 34143258
Drug: LV‐RBP (52.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV‐RBP (52.5 g of PMF104 in 500 mL of water)
Study: 34143258
Drug: FV‐RBP (105
Approvals — FDA: no, EMA: no, PMDA: no
Description: FV‐RBP (105 g of PMF104 in 1000 mL of water)
Study: 32423422
Drug: Local solutions
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local solutions implemented to strengthen LTBI management
Study: 33593307
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (OT) specialist consultation
Study: 33782959
Drug: TA (4
Normalized name: Triamcinolone acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TA (4 mg/mL) intradermal injections every 2 weeks
Study: 33782959
Drug: TA (10
Normalized name: {56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA (10 mg/mL) intradermal injections every 2 weeks
Study: 33782959
Drug: Topical TA
Normalized name: Doak 2% Topical Tar Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TA cream (10% concentration) twice daily
Study: 32176175
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy and observation
Study: 36763358
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg
Study: 32790904
Drug: Vortioxetine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine (15 mg/daily)
Study: 32790904
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/daily)
Study: 32790904
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/daily)
Study: 32790904
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg/daily)
Study: 32790904
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg/daily)
Study: 34006069
Drug: Guided bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided bone regeneration with titanium‐reinforced polytetrafluoroethylene membrane and simultaneous implant placement (Group A)
Study: 34006069
Drug: Guided bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided bone regeneration with titanium mesh and collagen membrane and simultaneous implant placement (Group B)
Study: 34534293
Drug: Maternal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal vitamin D sufficiency (25(OH)D ≥ 30 ng/ml) in the third trimester
Study: 34958861
Drug: 6'-Sialyllactose (6'-SL),
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6'-Sialyllactose (6'-SL), 3 g powder orally administered twice a day for 12 weeks
Study: 34958861
Drug: Placebo (maltodextrin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin), 3 g powder orally administered twice a day for 12 weeks
Study: 33755835
Drug: Serum CYR61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum CYR61 ≥ 236.2 pg/mL
Study: 33713473
Drug: Trapezius muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapezius muscle injection (TMI) with 5 mL of 0.25% bupivacaine two times, with a 1-week interval
Study: 33713473
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 20 mL of 0.125% bupivacaine in the second week after TMI
Study: 33713473
Drug: Repeated TMI
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated TMI (two injections)
Study: 32205201
Drug: PA2 -
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PA2 - 2 wt% proanthocyanidins solution applied for 60s
Study: 32205201
Drug: PA5 -
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PA5 - 5 wt% proanthocyanidins solution applied for 60s
Study: 34648685
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg PO daily)
Study: 34648685
Drug: Finasteride (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (2.5 mg PO daily) in combination with topical clindamycin 2% solution
Study: 36013498
Drug: Topical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical instillation of 0.3% ofloxacin, 4 drops at 15 min intervals before surgery
Study: 35178811
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg once a day)
Study: 32375754
Drug: iCBT (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-based cognitive-behavioral therapy) intervention for PTSD, 5 weeks duration, 10 writing assignments (twice a week)
Study: 32375754
Drug: iCBT (internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCBT (internet-based cognitive-behavioral therapy) intervention for PTSD
Study: 35018508
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg three times a day
Study: 34327833
Drug: Topical monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical monotherapy
Study: 34327833
Drug: Intensive approach
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive approach using drugs from three different classes plus 360° laser trabeculoplasty
Study: 32415720
Drug: CNTO 7160
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 7160 (3 mg/kg) in patients with AD
Study: 32415720
Drug: CNTO 7160
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 7160 (3 or 10 mg/kg) in patients with asthma or AD
Study: 32415720
Drug: CNTO 7160
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 7160 (1-10 mg/kg)
Study: 32415720
Drug: CNTO 7160
Normalized name: Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNTO 7160 (1 mg/kg IV every 2 weeks)
Study: 36071623
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=27) received four one-hour low back pain-related education sessions in addition to eight 45-minute standard physical therapy sessions over 4 weeks.
Study: 33694311
Drug: Lisinopril (ACEi)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (ACEi)
Study: 32072592
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (specific intervention not detailed)
Study: 36049646
Drug: RLRL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RLRL therapy (100% power)
Study: 35718656
Drug: tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tedizolid phosphate 200 mg once daily for 7 days
Study: 35034050
Drug: Demographic characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demographic characteristics (younger, college education, single, employed, Han ethnicity, diagnosed with HIV in the past 6 years, not on antiretroviral therapy)
Study: 33758387
Drug: Myo-inositol treatment
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Myo-inositol treatment
Study: 33113596
Drug: Riluzole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100 mg/d for 8 weeks)
Study: 35272400
Drug: Tramadol hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol hydrochloride injection, 1 mg/kg intravenously.
Study: 32518394
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate 0.15% ophthalmic solution
Study: 33234158
Drug: Ivermectin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Study: 33234158
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets of 6 mg for patients 48-80 kg, 3 tablets for 80-110 kg, 4 tablets for >110 kg) administered at inclusion and 24 hours later.
Study: 32281579
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g AZD0585
Study: 32281579
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g AZD0585
Study: 35718790
Drug: Maltodextrin and
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin and fructose beverage (800 mL at 10 hours and 400 mL at 2 hours before surgery)
Study: 33409924
Drug: No zinc
Normalized name: ZINC OXIDE 140 mg in 1 mL TOPICAL CREAM [Lucin Organics Tinted Sunscreen SPF 30 Non Nano Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No zinc therapy (Control)
Study: 36118673
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg daily) plus original oral hypoglycemic agents
Study: 36118673
Drug: Original oral
Normalized name: Sucrets Original Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original oral hypoglycemic agents alone (control group)
Study: 35908254
Drug: Masupirdine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masupirdine treatment
Study: 33597439
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered at the same frequency as the vitamin A supplementation)
Study: 35150610
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (250-300 mL of high anti-SARS-CoV-2 IgG titres methylene blue-treated convalescent plasma)
Study: 35150610
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mL of sterile 0.9% saline solution)
Study: 36342143
Drug: Baxdrostat 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat 0.5 mg